biote Corp. (NASDAQ:BTMD - Get Free Report) major shareholder Guines Llc bought 13,532 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average price of $3.21 per share, with a total value of $43,437.72. Following the completion of the acquisition, the insider now owns 4,156,426 shares of the company's stock, valued at $13,342,127.46. This trade represents a 0.33 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Guines Llc also recently made the following trade(s):
- On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The shares were bought at an average cost of $3.15 per share, for a total transaction of $136,640.70.
- On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The shares were purchased at an average price of $3.24 per share, with a total value of $23,720.04.
- On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The stock was purchased at an average price of $3.32 per share, for a total transaction of $351,920.00.
- On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The shares were purchased at an average cost of $3.74 per share, with a total value of $374.00.
- On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The stock was purchased at an average price of $3.22 per share, for a total transaction of $2,415,000.00.
biote Stock Down 4.6 %
biote stock opened at $3.35 on Friday. The firm has a market capitalization of $183.28 million, a P/E ratio of 12.88 and a beta of 1.17. The firm has a fifty day moving average of $4.09 and a 200-day moving average of $5.20. biote Corp. has a 52-week low of $3.04 and a 52-week high of $8.44.
Wall Street Analyst Weigh In
Separately, Craig Hallum dropped their target price on shares of biote from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday, March 13th.
View Our Latest Analysis on BTMD
Institutional Trading of biote
Large investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in shares of biote by 52.3% in the third quarter. Barclays PLC now owns 77,196 shares of the company's stock valued at $432,000 after buying an additional 26,510 shares in the last quarter. Kanen Wealth Management LLC acquired a new stake in biote in the fourth quarter valued at approximately $1,791,000. State Street Corp raised its stake in shares of biote by 13.7% during the third quarter. State Street Corp now owns 475,491 shares of the company's stock valued at $2,653,000 after purchasing an additional 57,290 shares during the period. Jane Street Group LLC lifted its position in shares of biote by 24.7% during the third quarter. Jane Street Group LLC now owns 16,873 shares of the company's stock worth $94,000 after purchasing an additional 3,342 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of biote in the fourth quarter valued at $76,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.
biote Company Profile
(
Get Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
